As PF progresses, it is wise to address how long to keep working. It is common to wonder: How do I know when to stop? When is work harmful to my health? Can I make it financially? How do I obtain disability or early retirement? These are…
The Pulmonary Fibrosis Foundation (PFF) is now accepting applications for a new program, called PFF Scholars, that aims to support and further develop promising researchers working in the field of pulmonary fibrosis (PF). The PFF Scholars program was designed to provide emerging researchers with financial resources to conduct or…
I have noticed a difference in myself over the past few months. I believe this new attitude is beneficial for my physical, mental, and emotional health. I have been prioritizing my needs and not feeling guilty about doing so. I encourage everyone to live and work this way,…
The Pulmonary Fibrosis Foundation (PFF) created an educational website to increase awareness about this disease, with a goal of promoting earlier diagnosis among pulmonary fibrosis (PF) patients. The website includes a video explaining the disease and outlining possible causes, stories from people with the disease, and offers a downloadable Pulmonary Fibrosis…
Living with any life-threatening illness is difficult and brings many changes, both to the patient and her family. Following my diagnosis of idiopathic pulmonary fibrosis (IPF) in early 2016, my doctor talked about the physical changes I should expect. What the doctor didn’t mention were the other —…
Researchers have uncovered an immunological mechanism that underlies fibrosis in different lung conditions, including sarcoidosis and idiopathic pulmonary fibrosis (IPF), a study reports. In mouse models of pulmonary fibrosis (PF), the study also demonstrated…
A pulmonary fibrosis diagnosis is difficult, to say the least. You need kindness, not just for others, but also for yourself. It helps to be compassionate with yourself during the stressful, scary, and difficult times. Talking to yourself with kindness is a powerful form of self-compassion. Kind truths…
Pharmaxis’ first small molecule inhibitor of LOXL2 (lysyl oxidase like 2), an enzyme that promotes fibrosis in the lungs of idiopathic pulmonary fibrosis (IPF) patients, was found safe and well-tolerated in healthy volunteers participating in a Phase 1 trial, the company announced. Additionally, treatment with the LOXL2 inhibitor, called…
For as long as I can remember, I’ve always loved meeting new people. My siblings and I each have unique talents. One of my brothers is exceptionally talented at music. He can pick up any instrument, learn to play it by ear, and join in any jam session.
Treatment with Esbriet (pirfenidone) can effectively benefit patients with idiopathic pulmonary fibrosis (IPF) who have more advanced lung function impairment, by preventing a decline in exercise capacity and worsening of shortness of breath (dyspnea). Those findings, taken from additional analysis of Phase 3 clinical trial data, were discussed…
Get regular updates to your inbox.
